Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PARG | Q86W56 | 1/20 | 0.30 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24828651 | 0.87 | KCNH2 (0.31) | — | |
| SCHEMBL24828389 | 0.85 | CRHR1 (0.33) | CRHR1 | |
| SCHEMBL24828421 | 0.84 | TLR7 (0.38) | TLR7CSF1RFGFR1FGFR4MEN1 | |
| SCHEMBL24828321 | 0.83 | TLR7 (0.38) | TLR7CSF1RFGFR1FGFR4MEN1 | |
| SCHEMBL25109731 | 0.79 | ADCY10 (0.35) | TLR7FGFR1FGFR4MEN1KMT2A | |
| SCHEMBL24828669 | 0.78 | HDAC6 (0.39) | CSF1RMEN1KMT2A | |
| SCHEMBL25109744 | 0.77 | ADCY10 (0.31) | — | |
| SCHEMBL25107934 | 0.77 | NTRK1 (0.33) | TLR7MEN1KMT2A | |
| SCHEMBL24828388 | 0.77 | NTRK1 (0.36) | MEN1KMT2A | |
| SCHEMBL24828317 | 0.76 | FGFR1 (0.35) | TLR7FGFR1FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542278-B1 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542278-B1 | Heteroaromatic macrocyclic ether chemotherapeutic agents | CYP2C8, ABCB1, CYP3A43 | TLR7 3615/4885CSF1R 4565/4885FGFR1 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.